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ORIGINAL ARTICLE
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Prevalence and Correlates of Coronary Vasomotion Disorders
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Margaret McEntegart, PhD; Stuart Watkins, MD; Hany Eteiba, MD; Aadil Shaukat, FRCP; Mitchell Lindsay, MD;  
Keith Robertson, PhD; Stuart Hood, MD; Ross McGeoch, MD; Robert McDade, BN; Peter McCartney, MBChB;  
David Corcoran, PhD; Damien Collison, MB BCh; Christopher Rush, MBChB; Bethany Stanley, MSc;  
Alex McConnachie, PhD; Naveed Sattar, PhD; Rhian M. Touyz, PhD; Keith G. Oldroyd, MD; Colin Berry, PhD
BACKGROUND: Determine the prevalence and correlates of microvascular and vasospastic angina in patients with symptoms 
and signs of ischemia but no obstructive coronary artery disease (INOCA).
METHODS: Three hundred ninety-one patients with angina were enrolled at 2 regional centers over 12 months from November 
2016 (NCT03193294). INOCA subjects (n=185; 47%) had more limiting dyspnea (New York Heart Association classification 
III/IV 54% versus 37%; odds ratio [OR], 2.0 [1.3–3.0]; P=0.001) and were more likely to be female (68% INOCA versus 
38% in coronary artery disease; OR, 1.9 [1.5 to 2.5]; P<0.001) but with lower cardiovascular risk scores (ASSIGN score 
median 20% versus 24%; P=0.003). INOCA subjects had similar burden of angina (Seattle Angina Questionnaire) but 
reduced quality of life compared with coronary artery disease; subjects (EQ5D-5 L index 0.60 versus 0.65 units; P=0.041).
RESULTS: An interventional diagnostic procedure with reference invasive tests including coronary flow reserve, microvascular 
resistance, and vasomotor responses to intracoronary acetylcholine (vasospasm provocation) was performed in 151 INOCA 
subjects. Overall, 78 (52%) had isolated microvascular angina, 25 (17%) had isolated vasospastic angina, 31 (20%) had 
both, and 17 (11%) had noncardiac chest pain. Regression analysis showed inducible ischemia on treadmill testing (OR, 
7.5 [95% CI, 1.7–33.0]; P=0.008) and typical angina (OR, 2.7 [1.1–6.6]; P=0.032) were independently associated with 
microvascular angina. Female sex tended to associate with a diagnosis of microvascular angina although this was not 
significant (OR, 2.7 [0.9–7.9]; P=0.063). Vasospastic angina was associated with smoking (OR, 9.5 [2.8–32.7]; P<0.001) 
and age (OR, 1.1 per year, [1.0–1.2]; P=0.032].
CONCLUSIONS: Over three quarters of patients with INOCA have identifiable disorders of coronary vasomotion including 
microvascular and vasospastic angina. These patients have comparable angina burden but reduced quality of life compared 
to patients with obstructive coronary artery disease. Microvascular angina and vasospastic angina are distinct disorders that 
may coexist but differ in associated clinical characteristics, symptoms, and angina severity.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03193294.
VISUAL OVERVIEW: A visual overview is available for this article.
Key Words: angina pectoris ◼ dyspnea ◼ microvascular angina ◼ prevalence ◼ quality of life
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Consensus guidelines for diagnosis and manage-ment of stable ischemic heart disease are pre-dominantly shaped by the burden of epicardial 
disease.1,2 Therefore, patients with symptoms and signs 
of ischemia and no obstructive coronary artery disease 
(INOCA) pose a challenge to treating physicians in both 
identification and manage.3 Microvascular angina (MVA) 
and vasospastic angina (VSA) are relevant causes that 
are rarely identified during coronary angiography.3–5 The 
reference diagnostic approach involves direct assess-
ment of coronary vascular function typically using phar-
macological probes.1–9
Wider developments in invasive coronary physiology 
coupled with better awareness of coronary vasomotion 
disorders have led to recently standardized diagnostic 
criteria.8,10–12 In the CorMicA study, we showed that an 
interventional diagnostic procedure (IDP: measurement 
of coronary flow reserve [CFR], microcirculatory resis-
tance [IMR], and vasomotor responses to intracoronary 
acetylcholine [ACh]) helped identify the cause of angina 
with tailored treatment improving symptoms and quality 
of life compared with standard care.7
In this prespecified CorMicA analysis, we analyzed 
the overall prevalence and predictors of MVA and VSA 
using a prospective all-comer study design incorporating 
reference invasive tests of coronary vascular function in 
patients with angina.
METHODS
Study Design and Participants
We screened elective adult referrals to 2 regional hospitals 
(Golden Jubilee National Hospital and University Hospital 
Hairmyres) providing invasive cardiac services to the West 
of Scotland (population 2.5 million). This all-comer design 
involved INOCA subjects being offered invasive testing as part 
of a prespecified analysis (CorMicA).13 The invasive protocol is 
summarized in the Data Supplement (Appendix). Outpatients 
undergoing clinically indicated, elective diagnostic coronary 
angiography for the investigation of angina were screened 
on the day of the procedure using the Rose angina question-
naire.14 Patients who provided a response consistent with defi-
nite or probable angina were invited to participate.14 Exclusion 
criteria included a noncoronary indication for invasive angiog-
raphy, for example, valve disease, cardiomyopathy, and inability 
to give informed consent. The ASSIGN Score is a validated 
cardiovascular risk score providing estimated 10-year risk of 
cardiovascular events incorporating social deprivation and fam-
ily history of cardiovascular disease.15 The West of Scotland 
Research Ethics Committee approved the study (reference 16/
WS/0192) and all subjects gave informed consent. The data 
that support the findings of this study are available from the 
corresponding author on reasonable request.
Interventional Diagnostic Procedure
Coronary thermodilution was used to measure CFR (abnormal 
<2.0,16 the index of microcirculatory resistance [IMR; abnormal 
≥25]17 and fractional flow reserve, abnormal ≤0.80)18 during intra-
venous infusion of adenosine (140 µg/kg per minute). ACh infu-
sions were followed by provocation testing for inducing epicardial 
spasm using 100 mcg bolus of ACh over 20 seconds (Figure I in 
the Data Supplement).
Definitions
• INOCA: syndrome of patients with either symptoms and/
or signs of ischemia but found to have no obstructive cor-
onary artery disease (CAD).3
◦   All subjects must have either definite (typical) or prob-
able (atypical) angina on Rose questionnaire.14
Nonstandard Abbreviations and Acronyms
ACh acetylcholine
BNP B-natriuretic peptide
CFR coronary flow reserve
CorCTCA  coronary microvascular function and CT 
coronary angiography
IDP interventional diagnostic procedure
IMR index of microcirculatory resistance
INOCA  ischemia and no obstructive coronary 
artery disease
MVA microvascular angina
oCAD obstructive epicardial disease
OR odds ratio
SAQ Seattle Angina Questionnaire
VSA vasospastic angina
WISE  Women’s Ischemia Syndrome 
Evaluation
WHAT IS KNOWN
• Angina without obstructive coronary artery disease 
is common and may be due to underlying disorders 
including microvascular angina and vasospastic 
angina.
• These patients are at elevated risk for cardiovas-
cular events (including acute coronary syndrome, 
repeated cardiovascular procedures, and heart fail-
ure hospitalization).
WHAT THE STUDY ADDS
• Over three quarters of patients with symptoms 
and signs of ischemia and no obstructive coronary 
artery disease have identifiable disorders of coro-
nary vasomotion including microvascular and vaso-
spastic angina.
• Traditional cardiovascular scores do not predict risk 
of coronary vasomotor disorders.
• Patients with ischemia and no obstructive coro-
nary artery disease have similar angina burden but 
worse quality of life than obstructive coronary artery 
disease subjects.
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• Obstructive CAD: ≥50% diameter stenosis and fractional 
flow reserve ≤0.80 during coronary angiography.
• VSA12: reproduction of angina symptoms, ischemic ECG 
changes with ≥ 90% constriction in major epicardial artery.
• MVA8: angina, no obstructive CAD plus objective evidence 
of coronary microvascular dysfunction (as defined by 
abnormal response to intracoronary ACh and/or systemic 
adenosine [CFR and/or IMR])
◦  CFR<2
◦  IMR≥25
• ◦   ACh response (microvascular spasm) defined by repro-
duction of angina, ST segment deviation (≥1 mm) and 
absence of significant epicardial coronary vasoconstric-
tion during ACh (<90% epicardial constriction)
• Mixed microvascular and VSA: angina with no obstructive 
CAD plus BOTH evidence of invasive coronary microvas-
cular dysfunction and epicardial vasospasm to ACh (≥90% 
epicardial constriction)
• Noncardiac chest pain: normal coronary vascular function 
during IDP assessment
• Myocardial bridging19: angiographic evidence of discrete 
systolic compression (milking effect ≥10% systolic com-
pression during the cardiac cycle)
• Endothelial dysfunction is defined by ≥20% luminal con-
striction during ACh infusion (up to 10−4 M).20
Statistical Methods
Statistical analyses were performed with Prism 7.0 (GraphPad, 
La Jolla, CA) and SPSS 25.0 (SPSS, Chicago, IL). Categorical 
variables are expressed as number and percentage of patients. 
Continuous variables are presented as means (SD) or median 
(IQR). Differences between groups were assessed using 1-way 
ANOVA, Mann-Whitney U tests, Chi squared, or Fisher exact 
tests as appropriate. Prespecified subgroup analysis of MVA 
and VSA groups was performed using unpaired t test. P value 
of ≤0.05 was considered statistically significant.
Binary logistic regression with MVA and VSA as outcomes 
was performed using prespecified variables of interest: sex, 
age, symptom characteristics, results from noninvasive exercise 
tolerance testing, cardiovascular risk factors (hypertension, dia-
betes, dyslipidemia, smoking, previous myocardial infarction), 
chronic pain disorders, and family history. Receiver operator 
curve were created for the models to see whether the vari-
ables could predict MVA or VSA as shown in Figure II in the 
Data Supplement. To assess discrimination of the regression 
model, we used the Harrell’s c-statistic corresponding to the 
area under the receiver operating characteristic curve to assess 
the goodness of fit and diagnostic accuracy.
Angina and quality of life assessment is detailed in the Data 
Supplement (Appendix).
RESULTS
Angina: Prevalence of Obstructive CAD and 
INOCA
Between November 25, 2016 and December 11, 2017, 
three hundred ninety-one patients with probable or defi-
nite angina were enrolled from 1386 elective referrals 
immediately before invasive coronary angiography. The 
majority of patients who were not enrolled lacked eligi-
bility criteria (Figure 1). Coronary angiography revealed 
obstructive CAD and no obstructive CAD in 206 (53%) 
and 185 (47%) subjects, respectively.
Demographics and Quality of Life Between 
CAD and INOCA
Subjects with obstructive epicardial disease (oCAD) tended 
to be older and have a higher prevalence of previous car-
diac events and dyslipidemia (Table II in the Data Supple-
ment). INOCA subjects were more likely to be female 
(68% versus 38% in oCAD; OR, 1.9 [1.5–2.5]; P<0.001) 
and have a higher incidence of chronic pain disorders at 
baseline (23% versus 10%; P<0.001). The INOCA popu-
lation were around 60% more likely to have undergone a 
previous invasive coronary angiogram (32% in INOCA ver-
sus 22% in oCAD; OR, 1.58 [1.01–2.48]; P=0.046).
Approximately two thirds of subjects in both groups 
underwent symptom-limited exercise treadmill testing as 
part of physician-reported standard care work-up. The 
presence of an abnormal exercise treadmill testing with 
inducible ischemia was higher in the oCAD group (81% 
versus 47%; P<0.001). Typical angina was more prevalent 
in the oCAD group (85% versus 64%; P<0.001) whereas 
the INOCA subjects had more limiting dyspnea (New York 
Heart Association classification III/IV 54% versus 37%; 
OR, 2.0 [1.3–3.0]; P=0.001). The angina severity scores 
showed a similar overall angina burden (SAQ summary 
score, 53.6 in oCAD versus 51.3 in INOCA; P=0.224). At 
baseline, most of the participants had daily or weekly angina 
(Seattle Angina Questionnaire, frequency score≈60), with 
mild to moderate angina limitation worse in the INOCA 
group (mean Seattle Angina Questionnaire, limitation 52.5 
versus 58.3; P=0.018). Quality of life at baseline assessed 
by EQ5D-5 L index was significantly lower in the INOCA 
group (0.60 versus 0.65; P=0.041).
INOCA: Prevalence of Vasomotion Disorders
Coronary vascular function was immediately assessed 
after diagnostic angiography in 151 of 185 INOCA par-
ticipants (Table 1). Thirty-four (18%) subjects did not 
have coronary function assessed because of logistical 
reasons or because of patient and clinician preferences. 
The mean age of subjects who underwent the IDP was 
60.9 (±10.0) years, and three quarters were female 
(n=111 [74%]). Figure 2A shows the different diagno-
ses within the INOCA population, Figure 2B shows the 
heterogenous nature of MVA with various types of CMD 
including both structural and functional disorders. Myo-
cardial bridging was noted in 22 (15%) subjects; how-
ever, we did not perform dobutamine challenge to assess 
the ischemic potential of the tunnelled segment. Approxi-
mately one-third of the study population who underwent 
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an IDP (34%,N=51) had a previous invasive coronary 
angiogram with no obstructive CAD (range, 1–5 previous 
angiograms).
The procedural characteristics are shown in Table 2. 
The target artery was the left anterior descending in 132 
subjects (87%) with no serious adverse events occur-
ring related to the IDP (Table I in the Data Supplement). 
Across the INOCA cohort, the mean fractional flow 
reserve was 0.88 (±0.06). Epicardial disease severity 
assessed using the Gensini score and fractional flow 
reserve were similar between the groups. Angiographi-
cally normal coronary arteries (no demonstrable lumi-
nal irregularities) were significantly more prevalent in 
the noncardiac cohort compared with the subjects with 
mixed MVA/VSA (OR, 6.53 [1.41–30.3]; P=0.016).
Multivariate Associates of MVA
In a logistic regression model with MVA as the outcome, tra-
ditional cardiovascular risk factors including risk assessed 
using the ASSIGN score were not associated with MVA 
(Table III in the Data Supplement). Ischemia on exercise 
treadmill testing was associated with MVA (OR, 7.5 [95% 
CI, 1.7–33.0]; P=0.008) and typical angina was also pre-
dictive (OR, 2.7 [95% CI, 1.1–6.6]; P=0.032). Female sex 
(OR, 2.7 [0.9–7.9]; P=0.063) and increasing age (OR, 1.1 
per year [1.0–1.2]; P=0.051) were positively associated 
with MVA, although the relationships were not statistically 
significant. The fitted regression model for MVA showed 
excellent discrimination (c-statistic, 0.85 [95% CI, 0.78–
0.92]; P<0.001; Figure II in the Data Supplement).
Multivariate Associates of VSA
In a logistic regression model with VSA as the outcome, age, 
and cigarette smoking were the only cardiovascular risk fac-
tors positively associated with the diagnosis (Table III in the 
Data Supplement). For every year increase in age, the odds 
of VSA grew by 10% (OR, 1.1 [95% CI, 1.0–1.2]; P=0.032). 
Higher traditional cardiovascular risk score (ASSIGN) was 
associated with a reduced risk of VSA (OR, 0.9 [0.9–1.0]; 
P=0.013). Inducible ischemia on exercise tolerance testing 
was associated with a reduced risk of VSA (OR, 0.3 [95% 
CI, 0.1–0.9]; P=0.040); however, angina characteristics (eg, 
atypical angina) were not associated with VSA diagnosis. The 
fitted regression model for VSA showed excellent discrimina-
tion (c-statistic, 0.82 [95% CI, 0.74–0.89]; P<0.001).
MVA and VSA: Quality of Life Differences
The VSA group had almost 20% lower overall angina 
summary score compared with MVA (Figure 3; mean 45 
versus 54 units; −9 [95% CI, −17 to −1]; P=0.028). VSA 
subjects had over 30% worse angina stability (mean 32 
versus 47 units; −15 [95% CI, −25 to −4]; P=0.009]) with 
24% lower angina-related quality of life (mean 34 versus 
45 units; −11 [95% CI, −21 to −1]; P=0.024). There were 
trends toward greater angina frequency (mean 52 versus 
62 units; −10 units [95% CI, −21 to 1]; P=0.067); how-
ever, this was not statistically significant (Figure 3; lower 
score indicates more severe angina). The EQ-5D-5L 
index revealed a 25% lower overall quality of life in the 
VSA group compared with MVA (mean, 0.5 versus 0.65; 
−0.15 units [95% CI, −0.28 to −0.02]; P=0.023). Notably, 
Figure 1. Study overview—
prevalence of coronary vasomotion 
disorders in ischemia and no 
obstructive coronary artery disease 
(INOCA).  
Figure showing screening and enrollment 
process with a total of 185 INOCA 
patients and 206 oCAD patients. IDP 
indicates interventional diagnostic 
procedure; MVA, microvascular 
angina; oCAD, obstructive epicardial 
disease; and VSA, vasospastic angina.
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Table 1.  Patient Demographics According to INOCA Endotype
MVA (N=78) VSA (N=25) MVA/VSA (N=31) Noncardiac (N=17)
P ValueMean or N SD/% Mean or N SD/% Mean or N SD/% Mean or N SD/%
Background
 Age 61.5 (10.7) 57.4 (9.1) 63.4 (8.6) 59.2 (8.9) 0.129
 Female 61 (78%) 15 (60%) 22 (71%) 13 (77%) 0.333
 BMI, kg/m2 30.7 (7.3) 29.7 (6.1) 29.7 (5.2) 31.4 (4.9) 0.752
 Smoker 9 (12%) 9 (36%) 9 (29%) 0 (0%) 0.001
 Previous MI 7 (9%) 5 (20%) 11 (36%) 1 (6%) 0.004
 Hypertension 54 (69%) 12 (48%) 20 (65%) 10 (59%) 0.030
 Previous stroke or TIA 10 (13%) 4 (16%) 4 (13%) 2 (12%) 0.975
 Diabetes mellitus 12 (15%) 6 (24%) 5 (16%) 6 (35%) 0.248
 Dyslipidemia 66 (85%) 15 (60%) 26 (84%) 12 (71%) 0.029
 FHx CAD 57 (73%) 15 (60%) 19 (61%) 14 (82%) 0.278
 COPD 13 (17%) 8 (32%) 7 (23%) 0 (0%) 0.183
 Chronic pain syndrome 16 (21%) 7 (28%) 10 (32%) 3 (18%) 0.516
 10-y risk* 26% (22) 22% (20) 23% (11) 30% (27.5) 0.525
 Prev angiogram† 24 (31%) 8 (32%) 16 (52%) 3 (18%) 0.081
Medication
 Aspirin 66 (85%) 23 (92%) 29 (94%) 13 (77%) 0.293
 β-Blocker 48 (62%) 16 (64%) 26 (84%) 11 (65%) 0.159
 CC blocker 31 (40%) 6 (24%) 8 (26%) 7 (41%) 0.315
 Nitrates 34 (44%) 11 (44%) 18 (58%) 8 (47%) 0.577
 Statin 67 (86%) 19 (76%) 28 (90%) 12 (71%) 0.218
 Nicorandil 10 (13%) 6 (24%) 8 (26%) 2 (12%) 0.281
 ACE inhibitor or ARB 35 (45%) 10 (40%) 13 (42%) 10 (59%) 0.641
Exam
 Systolic BP 140 (27) 128 (25) 134 (23) 145 (24) 0.108
 Diastolic BP 73 (12) 76 (18) 70 (12) 74 (10) 0.505
 Pulse, mmHg 73 (14) 70 (14) 66 (9) 67 (9) 0.066
Laboratory
 Hb, g/L 135.6 (13.8) 137.5 (10.9) 136.7 (15.1) 136.1 (16.1) 0.938
 Creatinine, mmol/L 76.7 (19.6) 82.9 (57.3) 77.6 (21.5) 72.5 (16.3) 0.938
 Cholesterol 3.4 (0.8) 3.3 (0.9) 4.0 (1.3) 3.7 (1) 0.042
 LDL 2.5 (1) 2.3 (0.9) 3.5 (0.9) 3.0 (1.6) 0.124
 Triglycerides 1.0 (0.6) 1.0 (0.6) 1.4 (1.3) 1.2 (0.7) 0.132
 Glucose 4.7 (1.4) 4.5 (1.1) 5.2 (2.7) 4.9 (1.1) 0.375
 HsCRP, ng/L 3.0 (4.1) 2.5 (3.6) 3.0 (4.1) 3.5 (7.2) 0.913
 HsTnT, ng/L 5.3 (3.3) 4.3 (3.6) 6.3 (4.1) 5.5 (3.7) 0.235
 NTproBNP, ng/L 146.1 (199.7) 116.8 (141.5) 166.5 (156.2) 161.1 185.9 0.763
 Stress ECG, pg/L 0.002
  Normal‡ 4 (5%) 2 (8%) 2 (7%) 5 (29%)  
  Inconclusive 23 (30%) 5 (20%) 5 (16%) 4 (24%)  
  Abnormal 31 (40%) 3 (12%) 9 (29%) 2 (12%)  
Symptoms
 Rose angina 0.132
  Definite (typical) 53 (68%) 12 (48%) 23 (74%) 9 (53%)  
  Probable (atypical) 25 (32%) 13 (52%) 8 (26%) 8 (47%)  
 Dyspnea 0.658
  NYHA I 8 (10%) 6 (24%) 4 (13%) 1 (6%)  
(Continued )
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the group with mixed MVA/VSA had similar angina char-
acteristics but 18% worse overall quality of life score com-
pared with the group with isolated MVA (EQ5D difference 
−12 units, −20 to −4; P=0.006).
There were notable differences in baseline character-
istics including smoking, dyslipidemia, and inducible isch-
emia on exercise treadmill testing. The mean age of VSA 
tended to be younger (−4.0 years [95% CI, −8.5 to 0.47]; 
Figure 2. Invasive assessment for 
coronary vasomotion disorders in 
angina.  
A, Shows different diagnoses within 
ischemia and no obstructive coronary 
artery disease (INOCA) population 
while (B) shows the heterogenous 
nature of microvascular angina. ACh 
indicates acetylcholine; CFR, coronary 
flow reserve; IDP, interventional 
diagnostic procedure; IMR, index of 
microcirculatory resistance (abnormal 
≥25); MVA, microvascular angina; and 
VSA, vasospastic angina.
  NYHA II 25 (32%) 5 (20%) 9 (29%) 7 (41%)  
  NYHA III 45 (58%) 14 (56%) 18 (58%) 9 (53%)  
HR-QoL
 Summary 53.6 (18.4) 44.5 (17.6) 46.8 (17.6) 54.3 (16) 0.069
 Limitation 53.8 (24.3) 47.6 (24.6) 47.0 (24.5) 60.5 (23.4) 0.206
 Stability 46.5 (23.7) 32.0 (23.4) 46.8 (22.1) 51.5 (28.6) 0.032
 Frequency 61.5 (23.4) 51.6 (19.9) 57.1 (24.9) 64.1 (25.3) 0.225
 Satisfaction 85.0 (16.7) 78.3 (26.3) 79.6 (18.4) 76.7 (21) 0.214
 Angina QoL 45.5 (20.7) 34.2 (25.1) 36.3 (22.1) 38.2 (17.2) 0.059
 EQ5D–Index 0.65 (0.28) 0.50 (0.32) 0.54 (0.28) 0.64 (0.24) 0.077
 EQ5D–VAS 70.4 (18.6) 60.6 (23.2) 58.6 (20.1) 69.4 (21.5) 0.018
P-value represents 1-way ANOVA for continuous variables or Fisher exact/χ2 for categorical variables (adjusted for multiple comparisons). ACE indicates angiotensin-
converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary 
disease; EQ5D, European quality of life 5 domain tool for standardized assessment of health outcomes; HR-QoL, health-related quality of life; HsCRP, high sensitivity 
C-reactive protein; HsTnT, high sensitivity troponin T; INOCA, ischemia and no obstructive coronary artery disease; LDL, low-density lipoprotein; MI, myocardial infarction; 
MVA, microvascular angina; NTproBNP, N-terminal pro b-type natriuretic peptide; NYHA, New York Heart Association functional classification of dyspnea; TIA, transient 
ischemic attack; and VSA, vasospastic angina.
*10-y risk estimated using validated ASSIGN score calculator.
†Previous invasive coronary angiogram (at least 1 previous study).
‡Proportion represents comparison with the whole subgroup population including those patients who did not undergo stress ECG testing.
Table 1.  Continued
MVA (N=78) VSA (N=25) MVA/VSA (N=31) Noncardiac (N=17)
P ValueMean or N SD/% Mean or N SD/% Mean or N SD/% Mean or N SD/%
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P=0.079) and systolic blood pressure lower compared 
with MVA (−12 mmHg; −23 to 0 mmHg; P=0.051).
DISCUSSION
In this prospective analysis of coronary vasomotion disorder 
prevalence, we used reference invasive diagnostic tests in an 
undifferentiated population of patients with angina undergo-
ing clinically indicated coronary angiography. The main find-
ings were: (1) around one half of patients with angina had 
symptoms and/or signs of ischemia but no obstructive CAD 
(INOCA); (2) disorders of coronary vasomotion are common 
in INOCA with over three quarters having a disorder of coro-
nary vascular function and symptom burden comparable to 
obstructive CAD; (3) MVA and VSA may coexist but differ in 
risk factor profiles, noninvasive investigations, angina symp-
toms and invasive coronary physiology.
Building on Prior Studies
The WISE (Women’s Ischemia Syndrome Evaluation) study 
evaluated baseline CFR invasively in 189 women with 
angina and no obstructive coronary arteries and identified 
74 (39%) patients with coronary microvascular dysfunc-
tion (defined as CFR≤2.32). The protocol did not involve 
universal administration of ACh during coronary reactiv-
ity testing.9 Aziz et al21 reported the largest case series of 
patients with INOCA in Europe (n=1379), with intracoro-
nary ACh testing (without adenosine) disclosing a high 
prevalence of vasomotor disorders including 26% with 
epicardial spasm and 33% with microvascular spasm, 
similar to our population. Sara et al reported a retrospec-
tive analysis of 1552 patients with INOCA in whom 64% 
had underlying CMD. Their protocol involved intracoronary 
Doppler measurements during simultaneous infusion of 
ACh and then adenosine to assess endothelium-depen-
dent and endothelium-independent function, respectively. 
The protocol did not involve provocation testing for coro-
nary vasospasm.22 Existing studies of disease prevalence 
may be prone to selection bias known as referral filter bias, 
by enrolling patients referred to tertiary care centers with 
a special interest in this problem.23,24 Lee et al described 
a cohort of 139 patients who had a diagnosis of INOCA 
based on invasive physiological testing combined with intra-
vascular ultrasound. ACh was administered into the LAD 
to assess endothelial function, although the conventional 
high dose bolus of ACh (100 mcg over 20 seconds) was 
given at a modified rate over 3 minutes. The short plasma 
half-life of ACh would render the intracoronary concen-
tration significantly lower in their study, which may explain 
Table 2. Procedural Characteristics: Invasive Evaluation of INOCA Subjects
INOCA (N=151) MVA (N=78) VSA (N=25) MVA/VSA (N=31) Non-Cardiac (N=17) P Value
Angiography
 Obstructive CAD* 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)  
 Angiographically normal 34 (23%) 18 (23%) 6 (24%) 3 (10%) 7 (40%) 0.095
 Myocardial bridging 22 (15%) 9 (12%) 6 (24%) 5 (16%) 2 (12%) 0.470
 Gensini score† 0 (0–0) 0 (0–0) 0 (0–1.5) 0 (0–0) 0 (0–0) 0.570
 LVEDP, mm Hg 9 (7–12) 9 (7–12) 9 (8–13) 10 (7–11) 8 (5–11) 0.452
Adenosine
 Rest
  Mean resting TT, s 0.78 (0.5–1.06) 0.81 (0.4–1.07) 0.67 (0.52–1.0) 0.78 (0.56–1.3) 0.82 (0.6–0.91) 0.734
  Pd/Pa 0.93 (0.92–0.98) 0.93 (0.84–0.94) 1.00 (1.00–1.00) 0.93 (0.93–0.93) 0.98 (0.96–0.99) 0.140
 Hyperemia
  Hyperemic TT, s 0.27 (0.20–0.39) 0.27 (0.21–0.41) 0.22 (0.17–0.26) 0.38 (0.32–0.54) 0.22 (0.16–0.27) <0.001
  FFR 0.89 (0.84 0.92) 0.89 (0.84–0.92) 0.86 (0.83–0.90) 0.89 (0.82–0.92) 0.88 (0.84–0.94) 0.718
  IMR 19 (15–29) 22 (15–31) 15 (14–18) 29 (20–38) 16 (12–19) <0.001
  IMR ≥25, n (%) 52 (34%) 31 (40%) 0 (0%) 21 (68%) 0 (0%) <0.001
  CFR 2.55 (1.83–3.48) 2.22 (1.67–3.42) 3.24 (2.70–3.82) 1.91 (1.58–2.77) 3.40 (2.97–4.53) <0.001
  CFR <2.0, n (%) 49 (33%) 32 (41%) 0 (0%) 30 (37%) 0 (0%) <0.001
Acetylcholine
 Microvascular spasm 49 (32%) 49 (63%) 0 (0%) 0 (0%) 0 (0%) <0.001
 Epicardial vasospasm 56 (37%) 0 (0%) 25 (100%) 31 (100%) 0 (0%) <0.001
 Endothelial dysfunction 70 (46%) 34 (44%) 15 (60%) 19 (61%) 2 (12%) 0.030
Data are N (%) or median (IQR). ACh indicates acetylcholine; CAD, coronary artery disease; CFR, coronary flow reserve; FFR, fractional flow reserve; IMR, index of 
microcirculatory resistance; INOCA, ischemia but no obstructive CAD; LVEDP, left ventricular end-diastolic pressure; MVA, microvascular angina; Pd/Pa, ratio of distal 
coronary pressure to aortic pressure at rest; VSA, vasospastic angina; and TT, transit time.
*Obstructive CAD defined as ≥50% diameter stenosis and FFR ≤0.80 during coronary angiography (vessels >2.5 mm).
†Angiographic score of epicardial CAD severity. For the MVA patients, 82 (75%) had an abnormal CFR and IMR, 18 (17%) had both CFR<2 and IMR≥25; 13 (12%) 
had CFR<2 and microvascular spasm to ACh; 14% had IMR≥25 and microvascular spasm to ACh; and 4 (4%) had all 3 findings.
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why no cases of epicardial vasospasm were identified. The 
Japanese established ACh testing for VSA and the 2014 
Japanese Cardiovascular Society guidelines on the invasive 
diagnosis of vasospasm using ACh established an intra-
coronary bolus dose of 20 to 100 µg administered over 20 
seconds.25 The higher rate of spasm in our study aligns with 
other published cohorts,26 and it is plausible that no subjects 
in their cohort were diagnosed with VSA due to the different 
ACh protocol. Interestingly, Lee’s cohort had similar levels 
of endothelial impairment as CorMicA subjects (44% ver-
sus 46%); nevertheless, microvascular function assessed 
with adenosine (CFR/IMR) was quite different. Abnormal 
vasodilator capacity (low CFR) was noted in only 7% versus 
33% in CorMicA and increased microvascular resistance 
(high IMR) was noted in only 21% versus 34% in our study. 
There are clear differences in the referral pathways and 
population studied that could explain these differences with 
CorMicA patients being nearly 10 years older on average, 
with more obesity, dyslipidemia, and greater cardiac risk. 
The enrollment period of 5-years implies that the popula-
tion (n=139 participants) was preselected. These studies 
have provided unique insights into the pathophysiology of 
INOCA but by design each had limitations raising uncer-
tainty about the prevalence and significance of vasomotor 
disorders. Our study had a consecutive approach to enroll-
ment during usual care and 151 subjects were included 
within 12 months.
In addition to showing that the majority of INOCA sub-
jects have demonstrable abnormalities in coronary vascu-
lar function, we showed they had more limiting dyspnea 
compared with oCAD subjects (New York Heart Asso-
ciation classification III/IV 54% versus 37%; OR, 2.0 
[1.3–3.0]; P=0.001). This is important given the emerg-
ing evidence that coronary microvascular dysfunction in 
INOCA subjects is closely linked with the syndrome of 
heart failure with preserved ejection fraction.27
Patel et al28 presented US data of 398 978 patients 
referred for coronary angiography, demonstrating that 
>60% had no obstructive CAD and 39% of patients had 
angiographically normal coronary arteries. More recent 
data are varied but the prevalence of no obstructive CAD 
was still almost 60% in the same groups most recent 
analysis of the national US cath PCI registry (almost 
700 000 elective coronary angiograms).29 The Ischemia 
trial had to exclude over 20% of patients with angina 
owing to no obstructive CAD on CT coronary angiogra-
phy despite moderate to severe ischemia on functional 
assessment.30 Other centers in the United Kingdom 
report at least 1/3 of patients with angina undergoing 
invasive coronary angiography have no obstructive CAD.31
MVA and VSA: Distinct Coronary Vasomotion 
Disorders
MVA and VSA may coexist,32 and 1/5 of the participants 
in our cohort had both disorders. Nevertheless, pre-
specified analysis of isolated MVA and VSA subgroups 
revealed important differences with implications for inves-
tigation and management of patients with INOCA. First, 
MVA and VSA subjects differed in risk factor profiles and 
associated characteristics. Traditional cardiovascular risk 
scores do not discriminate whether subjects have MVA. 
This has previously been highlighted by the iPower inves-
tigators.33 VSA was independently associated with older 
age and smoking but was interestingly inversely associ-
ated with traditional risk assessed by the ASSIGN score. 
VSA subjects were 3× as likely to have suffered a pre-
vious myocardial infarction but with lower prevalence of 
dyslipidemia compared with the patients with MVA. This 
is critical information which supports a different pheno-
type and underlying pathophysiology and supports identi-
fication with tailored therapies. This is evidenced by near 
identical prescribed therapies at baseline with 2/3 of 
both patients with MVA and VSA on β-blockers despite 
them being relatively contraindicated in VSA.2 The burden 
of medications for most subjects was substantial.
Interestingly, serum biomarker levels including inflam-
matory markers, troponin, and BNP (B-natriuretic pep-
tide) were similar between the INOCA groups. There are 
a few explanations for this but coronary vasomotor disor-
ders including coronary microvascular dysfunction have 
only weak correlation with these biomarkers.34 Other 
nontraditional risk factors may be more important in 
functional disorders. Furthermore, most of the subgroups 
were on established treatment before baseline bloods, 
which could confound and normalize the biomarkers.
Strengths and Limitations
Our study has several strengths. First, enrollment across 2 
regional centers providing care to a large population (2.5 
million) over a wide geographic area (half of Scotland), 
Figure 3. Differences in angina and quality of life between 
microvascular angina (MVA) and vasospastic angina (VSA).  
Figure showing the differences in angina and quality of life (QoL) 
score with VSA group having almost 20% lower overall angina 
summary score compared with MVA. SAQ indicates Seattle Angina 
Questionnaire.
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with a prospective, all-comer approach to enrollment of a 
comparatively large population increases the generalizabil-
ity of our findings. Second, participants underwent invasive 
characterization of coronary vasomotion using established 
diagnostic criteria with a comprehensive protocol aligned 
with international standards.8,12 The diagnostic accuracy of 
intracoronary ACh for diagnosing coronary spasm during 
invasive coronary angiography alone is excellent (sensitivity, 
90%; specificity, 99%).35 Third, this multimodality protocol 
provided novel insights into disease mechanisms and clini-
cal correlates, identifying distinct endotypes within an oth-
erwise undifferentiated population of patients. We designed 
the IDP to be performed on a single major epicardial artery 
(typically the LAD for pragmatic reasons); however, regional 
variations in microvascular function and propensity to epi-
cardial coronary spasm are well recognised.36,37 Further-
more, it was not possible to recruit all patients undergoing 
invasive angiography resulting in the potential for bias. 
Vasomotion disorder prevalence may vary according to local 
referral practices and multinational studies are warranted.
Our findings have wider implications, including the 
accuracy of noninvasive tests used for patients with 
stable chest pain in the clinic. Functional tests are rec-
ommended for diagnosing MVA2,8; however, anatomic 
testing with CT coronary angiography may result in false 
reassurance for patients with no obstructive CAD but 
underlying MVA and VSA. These patients are predomi-
nantly women.38 Discontinuation of therapy by protocol in 
patients with undiagnosed MVA may be one explanation 
for why CT coronary angiography-guided management 
was associated with more angina and poorer quality of 
life during longer term follow-up in the SCOT-HEART 
trial (Scottish Computed Tomography of the HEART 
Trial).39 The prevalence and clinical significance of vaso-
motor disorders in patients with angina classified with no 
obstructive CAD by CT coronary angiography is being 
prospectively assessed in the CorCTCA (Coronary Micro-
vascular Function and CT Coronary Angiography) study.
Conclusions
Around one half of suspected patients with angina under-
going invasive coronary angiography have symptoms and 
signs of INOCA. These patients report similar angina 
burden with worse quality of life than obstructive CAD 
subjects. The majority of INOCA subjects have underly-
ing disorders of coronary vasomotion (microvascular and 
VSA). Identification of these common disorders may facil-
itate patient education and distinct medical treatments.
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